National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Net benefit

Benefit (in monetary units) minus total cost (in monetary units)

Nivolumab plus ipilimumab (Opdivo® plus Yervoy®)

Opdivo® plus Yervoy® Is indicated for the treatment of advanced melanoma.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
27/06/2016  07/11/2016 Reimbursement Not Recommended at the Submitted Price.

Summary

The HSE has approved reimbursement following confidential price negotiations October 2017.